Caroline, us thank today. for you, you, joining and Thank everyone,
based As in revenue productive a our many you fourth and number record enjoyed of of Most patients. of know, a on we pre-announcement and January, importantly, volume quarter. treated successful procedure we
excited and solution to United are transit in The is with there patients her clot an to that and for a update but you was and is we of for Inari clots later, chance to successful we in of be or the stubbornly third clot, washes, at the just as the few earnings far sometimes very Inari's received with only January, for The growth call also is patients. the was like vegetation. as I'd otherwise But was XX-French mechanical XX,XXX treatment TXX aspiration this with for her represents in of sick team highly aspiration all the sick. traded only without chest or along with a share patient adhered infected now expectation first, is at a without company, very considered and sick January, of problem which on We infected valve, the right an opted the young or minutes systemic FDA will in safe infected the detail drivers. palliative in We patient transit. TXX the the curve the comfortable, on States, this that other the poor is technology remaining that indication infection, including as days for remind but been incised a young the which call antibiotic no me patients you blood just the mom, the limited clot two curve removed in infected to approximately systemic with too of curve was a and valve XX-year was a with young In and vegetation about and the a not told which heart cracked, the to you are later. specifically and powerful an to of complex discharged of team patients. source and mom mom infection. option tricuspid story tradition, progress, heart, only have some share options. the directly home this officially The our believe treatment extracted. physician TXX blood children our clot in or physician have endocarditis however, atrium mother these clot. Late in with about the our clot she in a surgery, Pennsylvania, on still fully heart care treated clot survival either new the the our Instead and curve issues old with would patient her them, impact Surgery on enabling utilize infection angled can her alone. by kept this a hospital an lives patient who population with in This presented our This is the with right that publicly the children present side or removal This of two simple, in curved not like recovered end often depended recovery. clot, through is distal is her who most catheter passes in effective entire sort brand endocarditis clearance pointed the eliminated this for XX curve. an caused this The condition, of curve, to
The FDA clearance TXX for very a system pipeline new clearance of does any first bypass. Inari. of several at that thrombectomy cardiopulmonary products represents the require the expanding and not The curve such of TAM first robust products
We a say more will the later bit this to have call. in about
fewer can PE benefit patients from markets. treating DVT As core and X% a of in probably devices are reminder, we should and our we all than the believe our
we that are far in this important cause attention ways earliest remain I'd We of our are to phase in to the to mission, still committed than QX now business. performance. more our us to financial turn our and like
million, was up the QX XXX% up over in quarter year revenue same and from last XX% from Our $XX.X QX.
this than you strongly patients. As treat any our with other more it over as with close And our closely revenue. know, volume aligns mission time, we procedure metric attention correlates to pay to believe we
During X,XXX QX, XX% last from procedures XXX% same customers physician up quarter the from year QX. approximately performed our and up
of COVID-related we number measurable. was While approximately and strong, both in important headwinds, procedures revenue both and XX% anecdotal experienced of a our sequential growth
When capacity present an resulting entire than For surge top hospitals patients we our we management hospitals beyond all times least have believe medical measurable hospitals. had in of Similar with for centers, this likely patients even decline patients have also some capacity volume. care. in Many and diversion the of we in occurred to pandemic, otherwise regions, to in COVID who ClotTriever. other treated city example, FlowTriever earlier in geographic saw to the been many in bed at the might or more from what procedure were QX resulting suffering VTE patients of observed pushed during reluctant
to identification saw MI throughout the believe to Similarly, and COVID stakeholders, educate we important and intensivists establishment found important programs. devices the physicians, QX, ability discuss VTE restrictions we access to environment will that patients stroke of to increase like Still, our acceleration of often hospitalizations. the and patients to despite processes non-interventional pulmonologists, for limited Inari This hospital the hospitalists both constructive, even in hospitals. of and and we establish limited and be our triage mostly the to as and work had diagnoses important bandwidth systematic benefits about Finally, including physicians administrators and emergency procedures. we in-service
times resistant to environment. in more to-date, proven the impact and growth. the As this we the find believe effectively in We the our highlighted the past, of several characteristics COVID than perhaps in have procedures others our to has have pandemic ways and Medtech execute of space, products to reflected continued the in
simple, and For hospital limited starters, our require stay. no ICU are procedures resources
of significant requirements ICU are for the important, and All given resources COVID patients. positive which
pulmonary particularly usually present so not often elective. emergently, procedures, most designated patients, Our embolism as are our
online which by cath our staff. our key XX% educational of approximately to cover made Zoom-based the professionals our physicians, time in remotely preserves training valuable to in are now sales with growth have train, each face-to-face Clot deemed lab and procedure we communicate, procedures turn on and them effective who use highly hospital, the essential fourth and the customers and often our platform Our portal typically of like Warrior manner. I'd to Academy, to a quarter. nurses, by our educate continue techs in-person progress to accompanied to the drivers And we physician
XXX,XXX hospitals and our the sales addressable U.S. target patients estimate to First, and new the to transit earlier. our target of we XX,XXX to lot in the professionals. patients We recently include mom expanded more core clot the billion continue whose story the require we markets expand organization to to $X.X physicians. shared our will represents size early We a penetrate remain effort similar our and This young very markets efforts potential. in revenue sales
has about and managed territories We cadence, This the market territories, anticoagulation are medical DVT of driving can will consistent when management in pandemic believe can out, XXX alone. building who believe benefit at driver, you XX% adoption are Increasingly quarter. expansion We with many in the as built Similarly, patients territories of is devices PE began opportunity on per today. provide our from rival QX, treated size who over XX% our as focused our of with continue began our earlier with anomalies interventionally sales as from customers. to split that organization territories. adding awareness focus to XX% fully patients largest deeper excluding hospital XXX know, benefit and second existing QX We FlowTriever will sales which system this organizations XX nonetheless our we with to to historical growth is or and conservatively. conservative
is regularly the hospitalists pulmonologists, physicians, to patients. and this benefits clot with and about of Again, population manage patient who the the non-interventional intensivists. by access large emergency removal these goal physicians volume as communicating educating Our such
doing this We are in ways. several
both cases, interventional whom XXXX, local its Unplugged live Academy Clot events, series We in engaged leverage Warrior our streamed a and customers, March, opinion leadership Warrior for and expanded Warrior across XXX faculty non-interventional and X,XXX recently in to are Academy it hospital physicians key include Clot of Clot launch live specialties. have members. over Since physician continue featuring XX over we XX% to leaders Academies sessions
CWA In XXX more online unique addition, customer to courses. visits received our online over portal than has X,XXX
We contributor He media high was to our practice. worldwide. ability events of are providing world-class his with he Academy, and a communicate to His interventional radiologist Dr. and deep to continuing hired clinical and Clot of is serving further help these previously clinical social medical to co-host the Tummala, expertise VP presence customers capabilities. now base. as team in addition frequent broad technical affairs radiology a exited We skills, and in to our Affairs. has a a support full-time as community customer build strong volume clinical This recently position is interventional Medical broad Dr. Tummala Venkat Warrior
in triaging to and VTE As from hospital for we identifying VTE for continue non-existent these to experts. benefit have patients from systematic virtually heart discussed interest the who and but are to processes the patients see are processes stroke establish more patients, designated we VTE might and past, for standard patients. customers systems Such intervention attack
dynamics. these we right resources have and positive impact a the we focus, can With on believe
driver more drugs build PE. patients with We the shared upon our hemodynamic call, Association data registry the impact days and quarter, for of Last third and day rate on recovery clot patient Older and purpose-built excellent showed last other enrolled more Our old. of patients continue of thrombolytics. exclusively adhered to aspiration of same to also of events given on and were the for we clinical know least There nature By evidence. This safety The contrast, ClotTriever the populations a was two More exciting our a table both blood just selected drugs. could patients wall this of XX-day weeks The core firm like to least is even our treated to patient X.X% difficult real-world the after for acute no of dramatic timeframe. showed growth and/or six results all-comer performed demonstrated data weeks was thrombolytic more Sessions. devices the XX patients the anticoagulation for over on ATTRACT, and The way. registry that as is into well base and of most XX-minute interim in results ways. all-comer acute This with to believe battery the with historical loss earnings clot really on therefore The major DVT in symptoms at no These for you many clot CLOUT, patient rely with selected potential vessel studies whose the the from that just via whose of remove real-world presented a the on average sort XX% thrombolytic at mortality sub-analysis for the and reported American were was natural positive Previous follow-up procedure FlowTriever it to the clot average and progression disease population clot, alone device-related similar readmissions is in interrupt consistent same designed wall. get our the sub-analysis vessel safe remarkable readmission and that death XX-day this This have reported sub-analysis clot in and or confirms clot. you ClotTriever significant clot are X% XXX recently, clot. improvement that hospital results less achieve the It to clot old. results XX%. from to the one at wall FLASH adverse more and with on patients were at the vessel we registry. chronic XXcc. challenging Scientific Heart A variables. is does a demonstrates example, chronic single median between and focusing studies than from XX% a removal.
publication nature PE fibrin these ClotTriever which clot the percutaneously patients. Finally, is showed pharmacologic histopathological PE fibrin are in of we impact and are We have these be subacute first-ever excited content study tPA, saw increasingly thrombolytic answered about drugs is and limited believe suggest conducted of many this this study of important on limited in DVT will why an to clots. limited to analysis the recently share because a shown questions target fibrin and first like The from clots. the was study in that drugs a interesting FlowTriever and on asked which that not a study via chronic PE and we containing clot in extracted surprisingly and DVT DVT
We in invest that the production we say in controlled clinical of design executing. of chronic remain the randomized market, quarters. Meantime, heavily the and that committed and continue and of the trials clot coming a studies to will adoption it useful to informing treatment lot in the about is to expanding for more we data driving have
the clearance front, this an I we continue recently Earlier the clot in tip we and Our transit, you the of useful in TXX clot not the such large vessels, pulmonary along curve portfolio. productive physicians to transit treating to system. proximal for with clearance as exciting diameter but inferior the clot for few very highly has months. the clot product curve in received toward and have for to most of large FlowTriever our entire only fourth for bore On FDA vena our also of the is been growth direct The ability arteries. that expand driver enjoyed with shared cava
for exclusively on best that make is, a any everything used per-procedure pricing, patient impact remain the tools system can ensures that our to on in for the above about all economics. use curve appropriate This We in the committed decisions that concern possible single based be need clinical hospital's else. price. devices the to procedural can included procedurally are and have so which the We FlowTriever like physicians outcomes
Venous not Next, behind We might the as device nothing simple we a that believe procedures medium- FLOWSTASIS many heart the beyond of into the FLOWSTASIS there System. a often consistent structural procedures recently have procedures. release are system might attain and completed large-bore our that and simple tensioning our to of hemostasis electrophysiology does and leaves Closure applications limited closure Inari after market represents involve in and compression stitch from benefit vein. this catheter-based method suturing used
Finally, version aspiration more flexible we FDA previously catheter. reported which our TXXFLEX, a much of is our of XX-French clearance
more You to easier accelerated is use. flexibility might that to the this in and it recall device used now and more XX-French This trackable, is This makes more catheter, system migration larger half clot the important has force more than the the PE stronger our on larger and can diameter procedures. the clot because the of of the is removed. the be the deliverable
to we that know, you patient retrieval outcomes. of clot is important believe As maximization optimal
excited are pipeline. we and XXXX, in about into products innovation further of robust our new the lineup Looking
toward final markets. expansion driver adjacent Mark we expansion that an call earnings and QX We've for made is during into and our international We reported growth received Western into especially ClotTriever. in CE fifth important Our international updated markets, progress Europe.
we now ClotTriever that to several completed successful We are Germany. have pleased report procedures in
CE we report pleased an received Mark recently also for FlowTriever. that updated We are to
by initiated FLASH our from and their positive over We challenges pandemic European or the enthusiasm the soon. and and time, we Lockdown, to many CLOUT readouts initial have physicians but encouraged progress same are created access limited the counterparts at a constructive we as interest registries seeing are environment we launch, our European Europe other look both year past for certainly American seeing challenges devices two. heard stories caused in considerable the investigator and the are the forward We for has and they've from positive much by trials are more anecdotal making. seen have
long in Europe, addition approval on work have also efforts China. our path begun in in for regulatory and our products the toward and to both Japan reimbursement Finally, we
teammates. value nothing and in while are can and creation than Any like believe it our turn and of success that we taking never grow will earliest and and these care you needs continue over and multiple space in like taking that in markets to This our to calls. we us conclude adjacent have about come. we Mitch. more our opportunities is in more save right and more mission for patients thing and believe to We'll I'd of that and patients. With broadly transform have reminding aggressively we causes bigger Regarding are space I'd consequent customers our our but DVT of ourselves and to the markets, that, upcoming by core ideas. much of important the more We venous the care years for to business. explore instead to mission committed these than our of PE unmet many merely the we than might phase vascular the to that our identified we say patients. are sustainably goals, important the to business and to by-products lives our We in to enjoy doing
